Logo - International Journal of Pharmaceutical Compounding

Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration

Author(s):  Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A

Issue:  Mar/Apr 2008 - Compounding Around the World
View All Articles in Issue

Abstract:  Palonosetron hydrochloride is a longer-acting selective 5-HT3 receptor antagonist that has been approved for the prevention of chemotherapy-induced nausea and vomiting and is being evaluated for the prevention of postoperative nausea and vomiting. The objective of this study was to evaluate the physical and chemical stability of palonosetron hydrochloride 50 mcg/mL when mixed with any of the neuromuscular blocking drugs cisatracurium besylate 0.5 mg/mL, rocuronium bromide 1 mg/mL, succinylcholine chloride 2 mg/mL, and vecuronium bromide 1 mg/mL during simulated Y-site administration. Triplicate samples of palonosetron hydrochloride with each of the neuromuscular blocking drugs were tested. Samples were stored and evaluated for up to 4 hours at room temperature. Physical stability was assessed by turbidimetric and particulate measurements and visual inspection. Chemical stability was assessed by high-performance liquid chromatography. All of the admixtures were clear and colorless when viewed in normal fluores

Related Keywords: Craig Trusley, PharmD, MS, Michel Ben, MS, Thomas C. Kupiec, PhD, Lawrence A. Trissel, BS, RPh, FASHP, compatibility, stability, palonosetron hydrochloride, selective 5-HT3 receptor antagonist, 5-HT3 blocker, nausea, vomiting, chemotherapy, neuromuscular blockers, cisatracurium besylate, rocuronium bromide, succinylcholine chloride, vecuronium bromide, drug admixtures, Y-site administration, infusion


Purchase this article for download in electronic PDF format from IJPC at for $35 at:

Search the entire IJPC archive by keyword, topic, or issue at: